In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

Event · Clinical / regulatory
Product
AL001
Milestone
discontinuation
Indication
bipolar disorder

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 17, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$ALZN
Bearish
high confidence
Mentioned
$ALZN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALZNBearishMed
01

Why it matters

The company received written FDA feedback on its proposed BD Phase II approach, paused the BD trial, and is preparing for a Type B meeting to revise the clinical development plan. MGH terminated the BD SOW, with a small refund, while the Healthy SOW and Healthy Patient Clinical Trial remain unaffected.

02

Market read

This is a development-plan and trial-execution reset for AL001 in bipolar disorder, driven by FDA feedback and followed by a BD trial pause and BD SOW termination.

03

What to watch

Healthy-subject Phase II work is completed and final results are expected in December 2026, which could partially offset BD-specific setbacks if data are strong.

Relevance 7/10Novelty 7/10Timing: Type B meeting planning, with expected FDA feedback by end of Q2 2027.

Background

Alzamend Neuro’s AL001 program uses a Master Clinical Trial Agreement with Massachusetts General Hospital (MGH) covering multiple Phase II indications via separate statements of work.

Company-level read

Ticker impact

$ALZNBearishHigh confidence
Context

Alzamend Neuro paused its Phase II BD trial after FDA feedback questioned whether AL001 trials were adequate and well-controlled for effectiveness evidence.

Expected impact

Likely downside pressure as investors price in higher regulatory uncertainty and a longer path to an NDA after the BD Phase II pause and SOW termination.

Evidence & confidence

The filing states the FDA did not support the proposed approach, the company paused the BD trial, and it plans to cease Phase II and move directly to Phase III, while BD SOW was terminated.

Market effects

Highlights FDA scrutiny on trial design adequacy for early-stage neuropsychiatric indications, potentially raising perceived regulatory bar for similar Phase II programs.

No direct regional market linkage beyond US biotech regulatory process.

US FDA feedback can affect global development timelines and investor sentiment for neuropsychiatric drug developers.

Counterpoint

The FDA feedback may still be constructive by steering the company toward a more supportable Phase III strategy, potentially improving the odds of an eventual NDA if the revised plan is executed well.

Key entities

  • Alzamend Neuro, Inc.

    Company filing the 8-K; developing AL001 for multiple neuropsychiatric indications.

  • AL001

    Investigational asset whose BD Phase II development plan was challenged by FDA feedback.

  • The General Hospital Corporation d/b/a Massachusetts General Hospital (MGH)

    Clinical trial partner under the Master Clinical Trial Agreement; terminated the BD SOW after the trial pause.

  • U.S. Food and Drug Administration (FDA)

    Provided written feedback indicating the proposed trials may not be adequate and well-controlled to support effectiveness evidence.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.

$DBMed

Data watchdog probes massive Deutsche Bank leak of 15M files

A German data regulator is investigating Deutsche Bank after a leak of 15M internal files. The probe focuses on data protection measures and timely reporting. CEO Christian Sewing acknowledged potential missteps. The leak, involving high-profile clients, has damaged the bank's reputation and affected its share price, though no sensitive account data was accessed.